Effects of dehydroepiandrostenedione, superimposed on growth hormone substitution, on quality of life and insulin-like growth factor I in patients with secondary adrenal insufficiency

Effects of dehydroepiandrostenedione, superimposed on growth hormone substitution, on quality of life and insulin-like growth factor I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-over trial / Sjoerd W. van Thiel, Johannes A. Romijn, Alberto M. Pereira, Nienke R. Biermasz, Ferdinand Roelfsema, Albert van Hemert, Bart Ballieux, Johannes W.A. Smit. - (Journal of Clinical Endocrinology & Metabolism 90 (2005) 6 (1 June); p. 3295–3303)

  • PMID: 15797966
  • DOI: 10.1210/jc.2004-1802


Abstract

To assess whether dehydroepiandrostenedione (DHEA) substitution, superimposed on GH substitution, improves quality of life of patients with secondary adrenal failure, we studied the effects of DHEA (50 mg/d, 16 wk) vs. placebo (16 wk) in GH- and ACTH-deficient men (n = 15; age, 52 +/- 3 yr), and postmenopausal women (n = 16; age, 61 +/- 2 yr) in a double-blind, placebo-controlled, crossover study. All patients were receiving stable hormone replacement therapy, including a fixed dose of human recombinant GH during the study. The men received testosterone substitution. The female patients did not receive estrogen substitution. At baseline, multiple parameters of quality of life were impaired compared with age- and sex-matched controls, especially in female patients. These parameters were not improved by DHEA treatment. DHEA only slightly improved the depression score (women) and health perception (women and men), although these parameters were not abnormal at baseline. DHEA increased serum IGF-I concentrations in female patients (by approximately 18%; P < 0.001), but not in male patients. In neither group did DHEA affect IGF-binding protein-3 levels. We conclude that DHEA, superimposed on GH substitution, does not substantially improve quality of life in patients with secondary adrenal insufficiency regardless of gender. In addition, DHEA increases IGF-I levels only in estrogen-depleted females, but not in testosterone-treated males, with secondary adrenal insufficiency.

Original document

Parameters

Science
Study
Date
1 June 2005
People
Ballieux, Bart
Biermasz, Nienke R.
Pereira, Alberto M.
Roelfsema, Ferdinand
Romijn, Johannes A.
Smit, Johannes W.A.
Van Hemert, Albert
Van Thiel, Sjoerd
Country
Netherlands
Language
English
Other organisations
Leids Universitair Medisch Centrum (LUMC) - Leiden University Medical Center
Doping classes
S1. Anabolic Agents
Substances
Prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one)
Medical terms
Health effects
Hormone replacement therapy (HRT)
Document type
Pdf file
Date generated
22 October 2020
Date of last modification
24 October 2020
Category
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period
Origin